论文部分内容阅读
目的:观察孟鲁司特辅助治疗迁延性肺炎的临床疗效。方法:将79例迁延性肺炎患儿随机分成两组,对照组38例给予常规治疗,观察组41例在常规治疗的基础上加用孟鲁司特治疗,2～5岁每次4mg,6～14岁每次5mg,每天1次,持续用药至症状、体征消失。结果:观察组总有效率92.7%高于对照组的78.9%,两组比较差异有统计学意义(χ2=6.162,P<0.05);观察组咳嗽、喘息、肺部体征消失时间及胸片肺部影像好转时间均短于对照组(P<0.05)。结论:孟鲁司特钠辅助治疗迁延性肺炎有助于缩短病程,且不良反应小,可作为迁延性肺炎的辅助治疗药物。
Objective: To observe the clinical efficacy of Montelukast adjuvant treatment of persistent pneumonia. Methods: A total of 79 children with persistent pneumonia were randomly divided into two groups. The control group received routine therapy. In the observation group, 41 patients were treated with montelukast on the basis of routine treatment, 4 mg each at 2 to 5 years, 6 ~ 14-year-old each 5mg, 1 day, continued medication to symptoms, signs disappear. Results: The total effective rate in the observation group was 92.7% higher than that in the control group (78.9%), the difference between the two groups was statistically significant (χ2 = 6.162, P <0.05); cough, wheezing, The time of partial image improvement was shorter than that of the control group (P <0.05). Conclusion: Montelukast adjuvant treatment of persistent pneumonia can help reduce the duration of the disease, and adverse reactions, as adjuvant treatment of persistent pneumonia.